Evidence map›Paper›PMID 21415064›Full record

ArticleTobacco control2011

Electronic nicotine delivery systems: a research agenda.

Jean-François Etter, Chris Bullen, Andreas D Flouris, Murray Laugesen, Thomas Eissenberg

Abstract read
In one paragraph

Article in Tobacco control, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Overview of Electronic Nicotine Delivery Systems: A Systematic Review.American journal of preventive medicine · 2017
    Pooled it
  2. An official American Thoracic Society/European Respiratory Society statement: research questions in COPD.European respiratory review : an official journal of the European Respiratory Society · 2015
    Pooled it
  3. Pooled it
  4. Cigarette Smoking Blunts Exercise-Induced Heart Rate Response among Young Adult Male Smokers.International journal of environmental research and public health · 2019
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Electronic cigarettes: effective nicotine delivery after acute administration.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2013
    Trial
  10. Article
  11. Article
  12. Vaping, Smoking and Lung Cancer Risk.Journal of oncology research and therapy · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. General and Device-Specific Reasons for ENDS Use: A Qualitative Study with Adult ENDS Users.International journal of environmental research and public health · 2022
    Article
  19. Review
  20. Article

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jean-François EtterInstitute of social and preventive medicine, University of Geneva, CMU, case postale, CH-1211 Geneva 4, Switzerland. jean-francois.etter@unige.ch
Chris Bullen
Andreas D Flouris
Murray Laugesen
Thomas Eissenberg

Funding

Waterpipe tobacco smoke: toxicant exposure and effectsR01CA120142 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI EISSENBERG, THOMAS EVAN · 2008 to 2012
$2.8M
Clinical models for evaluating PREPs for tobacco usersR01CA103827 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI EISSENBERG, THOMAS EVAN · 2004 to 2008
$2.1M
NCI NIH HHS R01 CA103827NCI NIH HHS R01 CA120142
6 · The paper itself

Abstract

Electronic nicotine delivery systems (ENDS, also called electronic cigarettes or e-cigarettes) are marketed to deliver nicotine and sometimes other substances by inhalation. Some tobacco smokers report that they used ENDS as a smoking cessation aid. Whether sold as tobacco products or drug delivery devices, these products need to be regulated, and thus far, across countries and states, there has been a wide range of regulatory responses ranging from no regulation to complete bans. The empirical basis for these regulatory decisions is uncertain, and more research on ENDS must be conducted in order to ensure that the decisions of regulators, health care providers and consumers are based on science. However, there is a dearth of scientific research on these products, including safety, abuse liability and efficacy for smoking cessation. The authors, who cover a broad range of scientific expertise, from basic science to public health, suggest research priorities for non-clinical, clinical and public health studies. They conclude that the first priority is to characterize the safety profile of these products, including in long-term users. If these products are demonstrated to be safe, their efficacy as smoking cessation aids should then be tested in appropriately designed trials. Until these studies are conducted, continued marketing constitutes an uncontrolled experiment and the primary outcome measure, poorly assessed, is user health. Potentially, this research effort, contributing to the safety and efficacy of new smoking cessation devices and to the withdrawal of dangerous products, could save many lives.

Indexed as

Biomedical ResearchConsumer Product SafetyElectrical Equipment and SuppliesSmokingAdministration, InhalationDrug Delivery SystemsHumansMarketingNicotineSmoking CessationNicotine

Identifiers

PMID21415064
PMCPMC3215262

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.